A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

Also called NCT02932410

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 165 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02932410
Other papers using this trial's data
  • Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial The Journal of pediatrics, 2026-06 DOI, PubMed 41796854

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Brazil, Canada, China, Colombia, Finland, France, Hungary, Israel, Malaysia, Mexico, Philippines, Poland, Portugal, Russia, South Africa, South Korea, Spain, Thailand, Ukraine, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02932410. Randomized; no masking; primary purpose treatment. Start 2017-10-24 (actual); primary completion 2024-08-28 (actual). Results posted on 2025-09-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
Acronym
TOMORROW
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan
Intervention (Other)
Standard-of-care
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct02932410
Content hash
b770bc7632d9374233101c2a3b624f5dfef776768f40c8aa62b6a6debd6f931a